MSTX Mast Therapeutics, Inc. Common

0.14
0  -2%
Previous Close 0.14
Open 0.14
Price To book 3.63
Market Cap 34.47M
Shares 254,746,000
Volume 6,279,635
Short Ratio 2.41
Av. Daily Volume 4,998,810

SEC filingsSee all SEC filings

  1. 8-K - Current report 17779754
  2. 425 - Prospectuses and communications, business combinations 17779749
  3. 8-K - Current report 17777312
  4. 425 - Prospectuses and communications, business combinations 17774986
  5. 8-K - Current report 17774954

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL received August 10, 2011.
Exelbine
Non-small cell lung cancer (NSCLC)
Phase 2 development to be discontinued 4Q 2016.
Vepoloxamer (MST-188)
Heart Failure
Phase 3 trial did not meet endpoints - September 20, 2016.
Vepoloxamer (MST-188)
Sickle cell disease
Phase 2 data due 4Q 2017.
AIR001
Heart failure with preserved ejection fraction (HFpEF)

Latest News

  1. Mast Therapeutics And Savara Announce Anticipated Merger Exchange Ratio
  2. Mast Therapeutics Announces Adjournment Of Special Stockholders Meeting
  3. Mast Therapeutics Announces Possible Adjournment Of Special Stockholders Meeting To Solicit Additional Votes For Merger With Savara
  4. Mast Reminds Stockholders To Vote For The Proposed Merger With Savara
  5. Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Mast Therapeutics Stockholders Vote "FOR" The Proposed Merger And Related Proposals
  6. Mast Therapeutics And Savara Announce Approval To List Common Stock On The Nasdaq Capital Market
  7. Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara
  8. Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Celldex Therapeutics and Mast Therapeutics
  9. Mast reports 4Q loss
  10. Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
  11. Mast Therapeutics Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients
  12. Mast Therapeutics To Merge With Savara Inc.
  13. Mast Therapeutics And Savara Sign Merger Agreement
  14. Mast Therapeutics Announces Initiation Of Patient Enrollment In Additional Phase 2 Study Of AIR001 For The Treatment Of Heart Failure With Preserved Ejection Fraction
  15. Mast Therapeutics 3Q Loss 8.2M or 4c/Share (MSTX)
  16. Positive Interim Results From Phase 2 Study Of AIR001 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (PH-HFpEF) Published In Journal Of Clinical Investigation
  17. Mast Therapeutics To Host Third Quarter 2016 Financial Results And Business Update Conference Call
  18. Research Reports on Biotech Equities -- Mast Therapeutics, Array BioPharma, Galena Biopharma, and Clovis Oncology